Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 3, 2006, Pages 437-444

  Metz, D C ^a   Comer, G M ^b   Soffer, E ^b   Forsmark, C E ^c   Cryer, B ^d   Chey, W ^e   Pisegna, J R ^f,g  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^e Rochester Institute for Digestive Diseases and Sciences   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAGALDRATE; PANTOPRAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTRECTOMY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HYPERSECRETION DISORDER; GASTROINTESTINAL SURGERY; HEART ARREST; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SEPSIS; SHORT COURSE THERAPY; STOMACH ACID SECRETION; TIME; TITRIMETRY; VOMITING; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACID; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; SULFOXIDES; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 33644892468     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02762.x     Document Type: Article

References (24)

1. Jensen RT Gardner JD Raufman JP et al. Zollinger-Ellison syndrome: current concepts and management Ann Intern Med 1983 98 59 75
2. Zollinger RM Ellison EH Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas Ann Surg 1955 142 709 23
3. Metz DC Jensen RT Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome In Mignon M Jensen RT eds Endocrine Tumors of the Pancreas. Frontiers in Gastrointestinal Research Vol. 23 Basel, Switzerland Karger 1995 240 57
4. Collen MJ Sheridan MJ Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation Dig Dis Sci 1991 36 1371 6
5. Norton JA Kivlen M Li M et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors Arch Surg 2003 138 859 66
6. Metz DC Pisegna JR Fishabeyn VA et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high Gastroenterology 1992 103 1498 508
7. Yu F Venzon DJ Serrano J et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome J Clin Oncol 1999 17 615 30
8. Gibril F Venzon DJ Ojeaburu JV et al. Prospective study of the natural history of gastrinoma in patients with MEN-1: definition of an aggressive and a nonaggressive form J Clin Endocrinol Metab 2001 86 5282 93
9. Norton JA Jensen RT Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN-1) Surg Oncol 2003 12 145 51
10. Hirschowitz BI Mohnen J Shaw S Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h Aliment Pharmacol Ther 1996 10 497 506
11. Jensen RT Metz DC Koviack PD et al. Prospective study of the long-term efficacy and safety of lansoprozole in patients with Zollinger-Ellison syndrome Aliment Pharmacol Ther 1993 7 Suppl. 1 41 50
12. Metz DC Strader DB Orbuch M Koviack PD Feigenbaum KM Jensen RT Use of omeprazole in patients with Zollinger-Ellison syndrome: a prospective nine-year study on efficacy and safety Aliment Pharmacol Ther 1993 7 597 610
13. Carswell CI Goa KL Rabeprazole: an update of its use in acid-related disorders Drugs 2001 61 2327 56
14. Desir B Poitras P Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome Can J Gastroenterol 2001 15 795 8
15. Hirschowitz BI Simmons J Mohnen J Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study Aliment Pharmacol Ther 2001 15 1785 806
16. Metz DC Soffer E Forsmark CE et al. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion Am J Gastroenterol 2003 98 301 7
17. Wolfe MM Jensen RT Zollinger-Ellison syndrome: current concepts in diagnosis and management Semin Gastrointest Dis 1987 317 1200 9
18. Orbuch M Venzon DJ Lubensky IA et al. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome Dig Dis Sci 1996 41 604 13
19. Maton PN Frucht H Vinayek R et al. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study Gastroenterology 1988 94 294 9
20. Pisegna JR Norton JA Sklimak GG et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirements in patients with Zollinger-Ellison syndrome Gastroenterologia 1992 102 767 78
21. Pisegna JR Martin P McKeand W Ohning G Walsh JH Paul J Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study Am J Gastroenterol 1999 94 2874 80
22. Metz DC Ferron GM Paul J et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study J Clin Pharmacol 2002 42 512 9
23. Frucht H Maton PN Jensen RT Use of omeprazole in patients with Zollinger-Ellison syndrome Dig Dis Sci 1991 36 394 404
24. Lloyd-Davies KA Rutgersson K Solvell L Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study Aliment Pharmacol Ther 1988 2 13 32